To determine whether there are differences in responses to thrombolytic therapy in certain populations, the data for the Thrombolysis and Angioplasty in Myocardial Infarction (phase 1) study were analyzed for black and white patients. Baseline variables including risk factors and extent of coronary artery disease were similar in the 352 white and 24 black patients. The time from onset of chest pain to recombinant tissue-type plasminogen activator (rt-PA) therapy and rt-PA dosing regimens were the same in the two groups. The patency rate of the infarct-related artery at 90 minutes was 91% for blacks and was 72% for whites (p=0.051). Blacks displayed significantly lower nadir fibrinogen levels (0.57±+0.62 versus 1.3+±0.76 g/l,p<0.0001), greater A fibrinogen (baseline-nadir) (2.7±+1.1 versus 1.7±1.1 g/l,p<0.0001), and increased peak levels of fibrin(ogen) degradation products (837+±865 versus 245±475 ,ug/ml, p<0.0001). rt-PA antigen levels tended to be higher in blacks than in whites (2.8+±2.2 versus 2.2±3.2 ug/ml [p=0.10] at the peakand 1.6±+1.3 versus 0.99±+1.4 ,g/ml [p=0.06] at the end of the maintenance infusion). Major clinical outcomes including survival until time of hospital discharge (92% black versus 93% white, p =0.68) were not significantly different. However, despite undergoing fewer angioplasty procedures (25% versus 46.3%, p=O0.047), blacks received more transfusions (58.8% versus 19.5% were administered >2 units packed erythrocytes, p=0.001). In conclusion, black patients have an apparent enhanced sensitivity to rt-PA, which is manifested by increased thrombolytic efficacy, a more pronounced systemic fibrinogen breakdown, and increased transfusions. (Circulation 1991;83:170-175) C oronary artery disease is the leading cause of death among black Americans.' Due in part to a higher prevalence of baseline risk factors including hypertension and diabetes mellitus,2 blacks exhibit a poorer prognosis after a myocardial infarction.2-4 It is, therefore, important to consider the differences that may exist in the responses to medical and surgical therapy between racial groups. Blacks appear to have a similar reduction in mortality to whites while receiving propranolol after a myocar-
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The relation between race and other major clinical outcomes is shown in Table 3 . Survival to discharge was the same for the two groups. Blacks and whites were equally likely to undergo coronary artery bypass grafting during the hospital period. However, white patients more frequently underwent coronary angioplasty, especially during the acute period because the 90-minute patency rate was lower in whites and the protocol mandated angioplasty of totally occluded vessels. 6 During the posthospitalization follow-up period, survival rates at 6 and 12 months were similar, but the number of deaths were too few to allow valid statistical comparisons (Table 3) .
Coagulation Parameters
Peak rt-PA antigen levels did not differ significantly between blacks and whites (Table 4) . However, there was a trend toward higher rt-PA levels in blacks during and at the end of the rt-PA infusion. Baseline fibrinogen levels were similar, but nadir fibrinogen levels were markedly lower for blacks (0.57±+0.62 g/l) than for whites (1.3+0.76 g/l). The A fibrinogen (baseline -nadir) was also much greater for blacks than whites.
When examined by the percentage of patients with nadir fibrinogen levels less than 0.5 g/l and less than 1.0 g/l, a striking difference was seen. More than 50% of blacks had nadir fibrinogen levels less than 0.5 g/l and more than 80% had nadir levels less than 1.0 g/l. Whites were generally resistant to severe fibrinogen depletion, and more than 60% had nadir fibrinogen levels greater than 1.0 g/l.
Commensurate with greater fibrinogen depletion, the black population also had significantly greater peak fibrin(ogen) degradation product levels. Peak D-dimer levels were similar in blacks and whites. Baseline plasminogen activator inhibitor levels were also similar between the two groups.
Hemorrhagic Complications
Major overt clinical bleeding including intracranial and gastrointestinal hemorrhage did not differ significantly between the two groups of nonsurgical patients (Table 5) . Moreover, the nadir hematocrit level and A hematocrit were similar in blacks and whites. Transfusion of 2 units or more of packed erythrocytes was required more frequently in blacks. Quantitative blood loss estimated by the formula of units transfused + A hematocrit/311 also tended to be greater in blacks. Discussion Results from the TAMI-1 study were examined to determine whether there are differences in the response to thrombolytic therapy with rt-PA between blacks and whites. Our patient populations were quite similar in relevant demographic and baseline characteristics. Surprising differences in therapeutic and hematologic responses were found that may affect both the success and the complications of fibrinolytic therapy with rt-PA in the black population.
Increased Patency of the Infarct Vessel
A trend toward higher patency at the 90-minute angiographic end point was observed in blacks. The 91% patency rate in blacks exceeds that in whites (72%, p=0.051) and is greater than that observed with any thrombolytic agent used alone or in combination, with the possible exception of rt-PA infused at a rapid rate.19 Factors that may be expected to increase the rate of reperfusion include the time from onset of chest pain to rt-PA therapy and the dose administered. However, these factors were essentially identical in the two groups (Table 1) . After reperfusion, the infarct-related vessel in blacks and whites had similar degrees of residual stenosis and reocclusion rates ( Table 2) .
The higher patency rates in blacks suggest altered pharmacology of rt-PA or an increased sensitivity to fibrinolysis at equivalent rt-PA levels. Tissue plasminogen activator antigen levels in both groups were widely variable and not significantly different (Table  4) , which is consistent with equivalent dosing regimens and volumes of distribution. There was a trend, however, toward higher rt-PA antigen levels in black patients at both peak and end of maintenance infusion time points. Tissue plasminogen activator is cleared predominantly by the liver,20,21 but hepatic blood flow must be reduced to less than 10% of normal to affect the pharmacodynamics of rt-PA. 22 Because none of these patients was in cardiogenic shock at hospital admission, a reduction of blood flow to that extent probably did not occur. Thus, intrinsic differences may exist in the hepatic clearance of rt-PA between blacks and whites, but more detailed pharmacological studies will be necessary to evaluate this question. Although population differences in the hepatic metabolism of certain drugs have been described,23 25 we are unaware of previous reports of significant race-dependent differences in rates of clearance of human recombinant proteins such as rt-PA.
Extent of Fibrinogen Depletion
As an indication of differences in the pharmacokinetics or pharmacodynamics of rt-PA in the two populations, blacks had significantly greater degradation of fibrinogen than did whites (Table 4) . Although baseline fibrinogen levels were equivalent, nadir fibrinogen levels were significantly lower in blacks than in whites. Greater fibrinogen depletion in blacks was also reflected in the greater magnitude of the A fibrinogen (baseline -nadir). In agreement with greater fibrinogen depletion, blacks also had higher peak fibrin(ogen) degradation product levels (Table 4) .
Peak D-dimer levels were not significantly different in the two populations despite differences in patency rates and extent of fibrinogenolysis. Previous studies have shown that D-dimer is a poor predictor of reperfusion,26.27 and our results are consistent with this observation.
Although the trend toward higher rt-PA levels in blacks at the end of the maintenance infusion may partially explain the increased fibrinogenolysis in this group, other factors should be considered. Further studies will be necessary to elucidate the exact mechanism(s) for the enhanced fibrinogenolysis during therapy with rt-PA now observed in US blacks.
The differences observed in patency rates and fibrinogenolysis did not affect major clinical outcomes such as survival to discharge or the necessity for revascularization by coronary artery bypass grafting (Table 3) . Blacks did have fewer angioplasty procedures, especially acute procedures, than did whites, reflecting the higher acute patency rates. In the 6-12-month follow-up period, there was a trend for more angioplasties in blacks than in whites, perhaps reflecting the decreased use of angioplasty in this population during the in-hospitalization period. However, the number of patients in the postdischarge group was too small to allow more meaningful comparisons.
Risk of Bleeding
The major complication of thrombolytic therapy is hemorrhage. The major contributors to bleeding are invasive procedures, especially coronary artery bypass grafting during the lytic period.10 Because cardiopulmonary bypass creates an additional set of hemostatic defects, only nonsurgical patients were examined for the bleeding associated with rt-PA administration. Major overt clinical bleeding rates at intracranial and gastrointestinal sites were similar between blacks and whites (Table 5 ). However, blacks received more transfusions than did whites, even though the nadir hematocrit level and A hematocrit (baseline-nadir) did not differ significantly. The difference in transfusion rates may indicate that packed erythrocytes were administered to some bleeding patients early in the course of the bleeding complication, thereby avoiding an exceptionally large drop in the hematocrit level. As a measure of bleeding, the more frequent transfusion rate in blacks correlates with their greater extent of fibrinogen depletion and higher fibrin(ogen) degradation product levels. Both of these factors have been significantly but weakly correlated with bleeding risk in prior studies.102829 The excess bleeding in blacks occurred despite fewer angioplasty procedures during the acute period, providing even stronger support for the association of increased transfusion requirements with fibrinogen depletion.
In conclusion, this study demonstrates differences between blacks and whites in the response to thrombolytic therapy with rt-PA. Because the black population in this study was relatively small, these findings must be viewed as preliminary, requiring confirmation by larger studies. Further investigation will also be necessary to determine whether the observed differences are due chiefly to higher rt-PA levels in blacks or to other factors. The increased 90-minute patency rate after treatment of blacks with rt-PA, if confirmed, may compensate for the reported worse prognosis of myocardial infarction in this population. However, this potential benefit should be weighed against the increased transfusion requirement. Furthermore, these findings raise the possibility that the rt-PA dosing regimen may need to be adjusted for blacks and other nonwhite races to achieve a maximal benefit to risk ratio. It is also important to recognize that large, randomized studies may not allow for accurate determination of race-dependent benefits and risks of therapy if disproportionately composed of restricted populations or if reported for the population as a whole.
